Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661 .

Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.

Author information

  • 1Chongqing Medical University, The First Affiliated Hospital, Department of Infectious Diseases, Chongqing 400016, China.



There has been a renewed interest in using polymyxin B as a last resort therapeutic option, due to emergence of multidrug-resistant Gram-negative bacteria. Despite being available for clinical use for decades, there is still a very limited understanding on many aspects of this agent.


To review what is known about polymyxin B and to identify missing information or gaps for future investigations.


Pertinent information was reviewed from published literature in English.


For optimal use of polymyxin B, a more thorough understanding is needed on standardized susceptibility testing, serum and tissue concentrations achieved, antibacterial activity when polymyxin B is combined with other agents, and mechanisms of resistance. A more precise characterization of the relationship between drug concentration and toxicity is also required.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk